---
title: "AstraZeneca's sonesitatug vedotin gets FDA priority review for advanced gastric cancers"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306076537.md"
description: "The FDA has granted priority review to AstraZeneca's sonesitatug vedotin for the second-line or later treatment of CLDN18.2-positive advanced gastric and gastroesophageal cancers. A regulatory decision is expected in Q2 2027. Phase III trials demonstrated a 42% reduction in the risk of death compared to investigator’s choice of therapy."
datetime: "2026-11-19T07:14:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306076537.md)
  - [en](https://longbridge.com/en/news/306076537.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306076537.md)
generator: "portal-rs"
---

# AstraZeneca's sonesitatug vedotin gets FDA priority review for advanced gastric cancers

-   FDA grants priority review to AstraZeneca’s sonesitatug vedotin for second-line or later treatment of CLDN18.2-positive advanced gastric and gastroesophageal cancers. \* A regulatory decision is expected in the second quarter of 2027. \* The Phase III trial showed a 42% reduction in the risk of death versus investigator’s choice of therapy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202611190201BITN\_\_**UKPR**SV\_20261119-BIT-1373-0) on November 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [AZ beefs up myasthenia gravis pedigree with US, EU Klygefa nods](https://longbridge.com/en/news/305697522.md)
- [AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy](https://longbridge.com/en/news/305633730.md)
- [AstraZeneca secures FDA approval for Imfinzi combo in MIBC](https://longbridge.com/en/news/305649865.md)
- [AstraZeneca's Baxfendy wins EU panel backing for hypertension treatment](https://longbridge.com/en/news/305456995.md)
- [REG - AstraZeneca PLC - Baxfendy recommended for approval in the EU](https://longbridge.com/en/news/305628944.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**